Sep 10 |
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
|
Aug 18 |
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
|
Aug 9 |
Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
Aug 7 |
Tango Therapeutics GAAP EPS of -$0.24, revenue of $19.87M
|
Aug 7 |
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
|
Jul 9 |
Cantor sees Tango benefitting from Ideaya's positive data
|
Jul 9 |
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts
|
Jun 5 |
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
May 23 |
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
|
May 23 |
Tango Therapeutics to discontinue development of TNG348 program
|